Editorial: A miracle cure for stem cell conflicts
By Sacramento Bee,
Sacramento Bee
| 07. 10. 2005
As many readers know, leaders of California's stem cell research institute have steadfastly refused to disclose the stock holdings and consulting relationships of scientists who will be recommending billions in research grants over the next decade.
The official explanation? Institute Chairman Robert Klein II and interim president Zach Hall claim that top scientists will refuse to "volunteer" for the institute's grant review panel (which pays $300 a day) if they are forced to publicly disclose their potential conflicts.
This page has spent weeks examining this claim. Frankly, it is a bunch of malarkey.
Throughout the scientific world, stem cell researchers are increasingly disclosing their corporate research relationships and stock holdings.
Some must do so if they want to serve as faculty on Continuing Medical Education courses sponsored by the Johns Hopkins School of Medicine and other medical schools.
Others must publicly disclose conflicts when their research is published in the New England Journal of Medicine, the Journal of the American Medical Association and other prestigious publications.
Consider the recent meeting of the International Society for Stem Cell Research, held in...
Related Articles
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
By Adam Zewe, MIT News | 02.07.2024
A tiny device built by scientists at MIT and the Singapore-MIT Alliance for Research and Technology could be used to improve the safety and effectiveness of cell therapy treatments for patients suffering from spinal cord injuries.
In cell therapy, clinicians...